Upregulated CLSPN was observed in patients with prostate cancer [8], renal cell carcinoma [10], gastric cancer [36], melanoma [37], anaplastic thyroid cancer [38] and other malignant diseases or animal models [39–41]. This evidence concerns the gene CLSPN and thyroid gland undifferentiated (anaplastic) carcinoma.